Neurocrine price target raised to $184 from $170 at Needham

Needham raised the firm’s price target on Neurocrine (NBIX) to $184 from $170 and keeps a Buy rating on the shares. The company reported a strong Q3, with EPS topping consensus thanks to better-than-expected product performance, the analyst tells investors in a research note. The management is again expanding its sales force by about 30% to continue driving Ingrezza volume growth ahead of IRA- related pricing pressure for Austedo starting 2027 and to broaden endocrinologist reach for Crenessity, the firm added, noting that Neurocrine remains well positioned to drive shareholder value with two scaled commercial assets and a deep, advancing pipeline.